Teprotumumab approved for thyroid eye disease
- Posted on: Jan 22 2020
- Leave a response
People with thyroid eye disease finally have a nonsurgical option for improving proptosis, thanks to the FDA’s approval of Horizon Therapeutics’ teprotumumab (Tepezza).
Source: AAO
Posted in: Uncategorized
